Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Medical World News

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

COPD

COVID-19

Cholangiocarcinoma

Chronic Kidney Disease

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Digital Health

Employers

Epilepsy

Heart Failure

Hematology

Hemophilia

Immuno-Oncology

Infectious Disease

Inflammation

Leukemia and Lymphoma

Liver

Lung Cancer

Lupus

Major Depressive Disorder

Medicare

Multiple Myeloma

Myasthenia Gravis

Myelodysplastic Syndromes

Oncology

Ophthalmology

Ovarian Cancer

Parkinson Disease

Prostate Cancer

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Rare Disease

Reimbursement

Respiratory

Rheumatology

Skin Cancer

Sleep

Spinal Muscular Atrophy

Type 1 Diabetes

Vaccines

Women's Health

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

eNewsletter

Gianna is an associate editor of The American Journal of Managed Care

 since 2019 and has a BA in philosophy and journalism & professional writing from The College of New Jersey. 

Articles

It’s estimated around 20% of patients will discontinue their first course of anti–tumor necrosis factor-α (anti–TNF-α) and rates increase over time

Review Identifies Criteria Used to Define Anti–TNF-α Failure in Patients With Psoriasis

Videos

Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer, discussed the study's broad population and potential payer reactions.

Dr Dennis Slamon on What Sets the NATALEE Trial Apart From Other Breast Cancer Studies

Results are based on a study of low-dose interleukin-2 (IL-2) carried out at Dana-Farber Cancer Institute. 


Real-world Evidence Finds Low-Dose IL-2 Safe, Well Tolerated in Steroid-Refractory GVHD

To the authors’ knowledge, the study is the first to include a patient with essential thrombocythemia (ET) and MPL and Type 1 calreticulin gene mutations.


Case Study Highlights Importance of Next-Generation Sequencing in Patients With ET 

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Interactive Tools

Updated Recommendations on Nonstatin Therapies for Managing LDL-C: Health System Considerations for ASCVD Risk Management

A Real-World Study Comparing Pre-Post Billed Annualized Bleed Rates and Total Cost of Care Among Non-Inhibitor Patients with Hemophilia A Switching from FVIII Prophylaxis to Emicizumab

Mitigating Cardiovascular Risk Through Lipid Management: From Hospital to Home

Improving Outcomes In Heart Failure Regardless of Lvef

Interchangeable Biosimilars: Key Points for Patients